These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The feasibility and mechanism of recombinant adenovirus Ad - p 14 ARF in gene therapy of liver cancer].
    Author: Song HF, Qian HL, Zhang XY, Liang X, Fu M, Lin C.
    Journal: Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):641-5. PubMed ID: 17274365.
    Abstract:
    OBJECTIVE: To explore the feasibility and mechanism of recombinant adenovirus Ad-pl4ARF in cancer gene therapy. METHODS: The proliferation of different liver cancer cells was assessed by morphology and trypan blue assay. Cell apoptosis was confirmed by detecting phosphatidylserine (PS) externalization with Annexin V/PI double staining. The expression of related proteins was analyzed by Western bloting. Nude mouse model bearing subcutaneous transplanted BEL7402 tumor was established to study the therapeutic ability of Ad-pl4ARF. RESULTS: Ad-pl4ARF suppressed cell growth and proliferation, and promoted cell apoptosis of cancer cell lines with different genetic background. Ad-pl4ARF inhibited growth of liver cancer cells ( HepG2, BEL7402) in a dose-dependent manner. Ad-pl4ARF lead to overexpression of Bax and p21, the downstream regulating genes of p53. In the experimental therapy on nude mice bearing subcutaneous transplanted BEL7402 tumor, Ad-pl4ARF suppressed tumor growth significantly. CONCLUSION: pl4ARF is a short gene and with powerful function, which are consistent with the requirements for tumor suppressor genes used in gene therapy. It may play an important role in gene therapy against malignancies in the future.
    [Abstract] [Full Text] [Related] [New Search]